Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep541 | Diabetes therapy | ECE2016

PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism as predictors of lipid-lowering response to statin therapy in patients with T2DM

Lebedeva Nadezhda Ol , K Vikulova Olga , Nikitin Alexei G , Shamkhalova Minara Sh , Shestakova Marina V

Aim: To evaluate the effect of PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism on the response to statins therapy in patients with type 2 diabetes mellitus (T2DM).Methods: We consecutively recruited patients with type 2 DM requiring lipid-lowering therapy according to current guidelines. Patients were started on either atorvastatin 10 or 20 mg. After 12 month of st...

ea0029p902 | Female Reproduction | ICEECE2012

The effects of the therapy with ethinylestradiol 30 μg-drospirenone+metformin on endothelial dysfunction in the polycystic ovary syndrome

Ilie I. , Ilie R. , Marian I. , Mocan T. , Hazi G. , Duncea I. , Georgescu C.

Introduction: Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at a greater risk for cardiovascular disease (CVD). The objective of this study was to evaluate the effect of the association ethinylestradiol 30 μg–drospirenone 3 mg (DRP/EE30 μg) plus metformin and weight loss on surrogate markers of CVD in PCOS.Methods: Twenty-five young women with PCOS (mean age 22.76±0.83 years, body mass index (BMI...

ea0029oc4.4 | Pituitary Basic | ICEECE2012

Identification of coupling specificity between somatostatin receptor 5 (SST5) and G proteins by a bioluminescence resonance energy transfer (BRET) technique: the role of GoA protein

Peverelli E. , Mantovani G. , Vitali E. , Busnelli M. , Chini B. , Lania A. , Beck-Peccoz P. , Spada A.

In this study we employed a novel bioluminescence resonance energy transfer (BRET) biosensor to study the coupling specificity of somatostatin receptor 5 (SST5) and its naturally occurring mutant R240W in living cells. Our previous data demonstrated that SST5 carrying the R240W mutation as well as other mutations in the third intracellular loop maintained the ability to inhibit intracellular cAMP levels similarly to the wild-type but failed to mediate the inhibition of intrace...

ea0056p931 | Female Reproduction | ECE2018

Pure leydig cell tumor of the ovary in young premenopausal female

Yesaulava Liudmila , Stinson Jeffrey A , Peltsverger Maya Y

Background: Leydig cell ovarian tumors (LCOT) represent a rare type of sex-cord stromal tumors accounting for less than 0.1% of all ovarian tumors. (1) Although rarely described in young, LCOT most commonly occur in postmenopausal women (2). The prominent clinical features of LCOT are rapidly progressive virilization, recently described, secondary erythrocytosis and OSA (3). Suppressed plasma leptin has also been reported in patients with LCOT (4), however direct correlation o...

ea0049gp47 | Bone & Calcium Homeostasis 2 | ECE2017

Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study

Clarke Bart L , Vokes Tamara J , Bilezikian John P , Bone Henry G , Denham Douglas S , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Shoback Dolores M , Warren Mark L , Watts Nelson B , Krasner Alan

Hypoparathyroidism (HPT) is characterised by hypocalcaemia and impaired renal phosphate excretion and calcium conservation. Oral calcium supplements and calcitriol can improve serum calcium levels but lack the physiologic effects of PTH on renal reabsorption of calcium. RACE is an ongoing open-label study evaluating the long-term safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84], parathyroid hormone rDNA) in adults with HPT (NCT01297309). In this interim analys...

ea0063gp15 | Calcium and Bone 1 | ECE2019

Recombinant human parathyroid hormone 1–84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study

Bilezikian John P , Bone Henry , Clarke Bart L , Denham Douglas , Germak John , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Sherry Nicole , Shoback Dolores M , Vokes Tamara J , Warren Mark L , Watts Nelson B

Background: RACE is an open-label study that assessed the long-term safety and efficacy of recombinant human parathyroid hormone 1–84 (rhPTH[1–84]) for the treatment of hypoparathyroidism in adults (ClinicalTrials.gov identifier NCT01297309). Here, we present 6-year safety and efficacy data.Methods: Patients initially received 25 or 50 μg of rhPTH(1–84) subcutaneously, once daily, with stepwise dose adjustments of 25 μg (up or do...

ea0050p046 | Bone and Calcium | SFEBES2017

Systematic in silico evaluation of rare genetic variants in G-protein alpha 11 (Gα11)

Gluck Anna , Gorvin Caroline M , Thakker Rajesh V

The calcium-sensing receptor (CaSR) is a G-protein coupled receptor (GPCR) that maintains systemic calcium homeostasis by detecting alterations in extracellular calcium, which it transduces into signalling changes, mainly via the Gq/11 pathway, leading to a decrease in PTH secretion. The importance of CaSR is highlighted by studies of patients that harbour germline CaSR mutations, which lead to a gain of receptor function in autosomal dominant...

ea0050p046 | Bone and Calcium | SFEBES2017

Systematic in silico evaluation of rare genetic variants in G-protein alpha 11 (Gα11)

Gluck Anna , Gorvin Caroline M , Thakker Rajesh V

The calcium-sensing receptor (CaSR) is a G-protein coupled receptor (GPCR) that maintains systemic calcium homeostasis by detecting alterations in extracellular calcium, which it transduces into signalling changes, mainly via the Gq/11 pathway, leading to a decrease in PTH secretion. The importance of CaSR is highlighted by studies of patients that harbour germline CaSR mutations, which lead to a gain of receptor function in autosomal dominant...

ea0063p365 | Thyroid 1 | ECE2019

Comparison of G-CSF and non-G-CSF treatment of agranulocytosis in patients with hyperthyroidism: a meta-analysis

Wang Yonghui , Li Xiaoying , Yang Qian , Zhang Yanan , Liu Jun , Zheng Liang , Zha Bingbing

There are potential benefits and risks to receive Granulocyte-Colony Stimulating Factor (G-CSF) as a general treatment in hospital. To assess the clinical effect of G-CSF or non-G-CSF on recovery duration for agranulocytosis patients with hyperthyroidism, we analyzed the overall clinical outcomes by meta-analysis. We included published seven retrospective studies and 1 prospective study. Individual data were obtained from eight trials (376 patients: 215 with G-CSF, 161 with no...

ea0026p369 | Signal transduction | ECE2011

Different and common transmembrane activation mechanisms between glycoprotein hormone receptors and other G-protein coupled receptors

Hoyer I , Kleinau G , Haas A K , Kreuchwig A , Grzesik P , Worth C L , Schuelein R , Krause G

The aim of our study is to identify signalling sensitive residue positions of the glycoprotein hormone receptors (GPHR), especially the thyrotropin receptor (TSHR) on the transmembrane helices (TMH) 5 and 6, knowing to be involved in GPCR activation. We performed modelling driven site-directed mutagenesis to pinpoint residues that are responsible for stabilization of active and inactive conformations of the TSHR.We highlight two amino acids that are high...